CYCC
NASDAQCyclacel Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$6.34+1.05 (+19.76%)
2025-06-162025-09-11
Latest news
25 items- SECCyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Bio Green Med Solution, Inc. (0001130166) (Filer)
- INSIDERNew insider Fitters Diversified Berhad claimed ownership of 699,158 shares (SEC Form 3)3 - Bio Green Med Solution, Inc. (0001130166) (Issuer)
- SECSEC Form 425 filed by Cyclacel Pharmaceuticals Inc.425 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)
- SECCyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)
- SECSEC Form EFFECT filed by Cyclacel Pharmaceuticals Inc.EFFECT - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)
- PRBio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd.KUALA LUMPUR, Malaysia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ:BGMS, NASDAQ:BGMSP) ("Bio Green Med" or the "Company"), a company engaged in diversified industries, today announced that it has closed the previously announced transaction (the "Exchange Transaction") to acquire Fitters Sdn. Bhd. ("Fitters"), a Malaysia private limited company and wholly-owned subsidiary of FITTERS Diversified Berhad, a Malaysian publicly listed company ("Fitters Parent"). Following the closing of the Exchange Transaction, which was approved by the Company's stockholders during a Special Meeting that took place on September 4, 2025, Fitters became a wholly-owned subsidiary of t
- INSIDERLarge owner Kua Khai Loon sold $133,569 worth of shares (19,054 units at $7.01), decreasing direct ownership by 5% to 385,411 units (SEC Form 4)4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
- SECSEC Form 425 filed by Cyclacel Pharmaceuticals Inc.425 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)
- SECCyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)
- SECCyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)
- INSIDERLarge owner Ong Yee Lung acquired 186,465 shares, increasing direct ownership by 86% to 404,465 units (SEC Form 4)4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
- INSIDERLarge owner Yap Kim Choy acquired 186,465 shares, increasing direct ownership by 86% to 404,465 units (SEC Form 4)4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
- INSIDERLarge owner Kua Khai Loon acquired 186,465 shares, increasing direct ownership by 86% to 404,465 units (SEC Form 4)4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
- SECSEC Form POS AM filed by Cyclacel Pharmaceuticals Inc.POS AM - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)
- INSIDERNew insider Ong Yee Lung claimed ownership of 218,000 shares (SEC Form 3)3 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
- INSIDERNew insider Kua Khai Loon claimed ownership of 218,000 shares (SEC Form 3)3 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
- INSIDERNew insider Yap Kim Choy claimed ownership of 218,000 shares (SEC Form 3)3 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
- SECCyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)
- SECCyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)
- SECSEC Form DEFA14A filed by Cyclacel Pharmaceuticals Inc.DEFA14A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)
- SECSEC Form 425 filed by Cyclacel Pharmaceuticals Inc.425 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)
- SECSEC Form 424B3 filed by Cyclacel Pharmaceuticals Inc.424B3 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)
- SECSEC Form POS AM filed by Cyclacel Pharmaceuticals Inc.POS AM - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)
- SECSEC Form 10-Q filed by Cyclacel Pharmaceuticals Inc.10-Q - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)
- SECSEC Form 425 filed by Cyclacel Pharmaceuticals Inc.425 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)
CYCC FAQ
6 questionsWhat does Cyclacel Pharmaceuticals Inc. do?
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs...Where does CYCC stock trade?
Cyclacel Pharmaceuticals Inc. (CYCC) is listed on NASDAQ.What sector and industry is CYCC in?
Cyclacel Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CYCC?
Cyclacel Pharmaceuticals Inc. has had 1 recent analyst action on file. The most recent action was from Oppenheimer: Outperform with a $1700.00 price target on 2022-07-18. Recent price targets cluster around $1700.00.What companies are similar to CYCC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CYCC side-by-side with any of them on Quantisnow.How can I track CYCC on Quantisnow?
Quantisnow aggregates Cyclacel Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CYCC to receive live email and push alerts on every new disclosure.